• 한국방사선학회논문지
• /
• 제17권4호
• /
• pp.573-579
• /
• 2023

본 연구는 자동노출조절장치를 사용하는 흉부 후·전 방향 방사선검사(Chest PA) 시 격자 사용 유·무 및 가상격자 사용에 따른 선량과 영상 품질의 차이 비교를 통해, Chest PA 시 임상적으로 새로운 격자 조합을 제안하고자 한다. 본 연구는 인체모형팬텀을 대상으로 Chest PA 자세에서 진행했다. 선량계는 흉추 6번 높이에 위치하였고, 조사 조건은 110 kVp, 320 mA, 1.6 mAs, SID는 180 cm, 조사야 크기는 17" × 17"로 동일하게 적용하였다. 물리적 격자를 적용한 상태와 미적용 상태에서 각각 30개의 영상을 얻었고, 물리적 격자 미적용 영상에 가상격자를 적용한 영상 30개를 추가로 획득하였다. 선량은 입사표면선량(ESD)을 측정하였고, 화질은 신호대잡음비(SNR)와 대조도대잡음비(CNR)를 측정하여 비교 분석하였다. 본 연구 결과 ESD는 물리적 격자를 사용하지 않을 경우 약 48%의 감소 효과가 있었다. SNR은 물리적 격자 미사용 시가 사용 시보다 약 32% 증가하였고, 가상격자를 사용한 경우에는 격자 사용 시 보다 약 18% 증가하였다. CNR은 물리적 격자 미사용 시가 사용 시보다 약 30% 증가하였고, 가상격자를 사용한 경우에는 격자 사용 시보다 약 16% 증가하였다. 본 연구의 결과, 물리적인 격자 대신 가상격자 사용 시 영상의 품질은 유지하되, 환자 선량은 감소시킬 수 있을 것으로 생각된다.

• Journal of Korean Neurosurgical Society
• /
• 제29권12호
• /
• pp.1673-1676
• /
• 2000

Anticonvulsant hypersensitivity syndrome is a rare but fatal complication. It manifests as fever, skin rash, lymphadenopathy, and hepatitis. Phenytoin, phenobarbital, and carbamazepine are the most frequently involved drugs. We here report a case of phenytoin-induced anticonvulsant hypersensitivity syndrome. A 37-year-old woman presented with fever and generalized skin rash, 3 weeks following commencement of phenytoin 400mg daily for treatment of seizure after superficial temporal artery-middle cerebral artery(STA-MCA) anastomosis for moyamoya disease. Her temperature was $39.3^{\circ}C$ and her face was edematous. Laboratory findings showed elevated hepatic enzymes and eosinophilia. Blood and urine culture were all negative. Initially, prednisolone was commenced at 30 mg daily. But fever and skin rash did not improved and hepatic function was more aggravated. After increasing dose of steroid(methylprednisolone 125mg/day), fever and skin rash disappeared and hepatic enzymes returned to normal range.

• 한국임상수의학회지
• /
• 제41권1호
• /
• pp.49-53
• /
• 2024

A two-year-old, spayed female, 22.5 kg Pungsan was referred with chronic crusts and erosion on the nose. A referring veterinarian prescribed an anti-inflammatory dose (0.5-1 mg/kg/day) of oral glucocorticoids for 5 months, but skin lesions showed no meaningful improvement. A dermatological evaluation revealed a crust, depigmentation, erosion, and erythematous lesion over the nasal planum with a loss of the normal cobblestone texture. Also, firm and multifocal plaques over the thigh, groin, axilla, and dorsum were detected. A cytology examination on the nose, thigh, groin, axilla, and dorsum revealed moderate neutrophilic inflammation and bacterial infection. Abdominal radiography and ultrasonography revealed subcutaneous calcified materials along the thigh, groin, axilla, and dorsum. Calcinosis cutis was suspected because of the adverse effect of previous prolonged corticosteroid therapy. A histopathology examination of the nose lesion revealed moderate to severe degenerative or apoptotic changes of the basal layer and lymphoplasmacytic interface dermatitis. Facial discoid lupus erythematosus (FDLE) was diagnosed based on the history and the clinical, cytological, and histopathological results. Minocycline (7 mg/kg PO q 12 h) and niacinamide (500 mg/dog PO q 12 h) were prescribed as initial treatment. Glucocorticoids were not administered due to the presence of calcinosis cutis induced by previous corticosteroid treatment. After 6 weeks of treatment, the clinical signs on the nose were mildly improved. At this time, topical 1% pimecrolimus cream (twice daily) was initiated, while minocycline and niacinamide were continued at the same dose. The nasal planum markedly improved after 6 weeks of additional treatment, hence minocycline and niacinamide were prescribed for an additional 2 weeks and stopped, and the patient was continued solely on topical pimecrolimus. The dog's skin lesion has been maintained in clinical remission with topical 1% pimecrolimus twice daily for more than 5 months.

• 대한유전성대사질환학회지
• /
• 제10권1호
• /
• pp.59-66
• /
• 2010

Enzyme replacement of therapy (ERT) is one of the most promising therapeutic strategies for the treatment of lysosomal storage disorders. ERT is available in three types of Mucopolysaccharidosis (MPS): for MPS I (Aludrazyme$^{(R)}$), MPS II (Elaprase$^{(R)}$) and MPS VI (Naglazyme$^{(R)}$) patients who are over 5 years old. But recently, early diagnosis can be done by expert clinicians and even in prenatal case. We describe the case of ERT under 5 years old MPS patients. Up to June, 2010 in Samsung Medical Center, there are 6patients who were diagnosed as MPS and started ERT under 5 years old. 3 patients were MPS I, 3 patients were MPS II. 2 patient who was diagnosed as MPS I was female and others were male. Their age at diagnosis were 4 to 37month-old (4, 13, 16, 25, 27, 37 month-old) and they are now 9 to 60 month-old (9, 39, 32, 81, 60 month-old). The youngest patient was started ERT at 4 month-old and others were started at their 13 to 49 month-old (13, 29, 27, 28, 49 month-old). First manifested symptoms of patients were macrocephaly, kyphosis and coarse face appearance. Especially, in 2 of them, one was MPS I and the other was MPS II had elder brother with same disease. And the youngest one was diagnosed by the iduronate-2-sulfatase (IDS) gene analysis from chorionic villi sampling. His mother knew that she was a heterozygous carrier of IDS gene mutation because her younger brother died from MPS II. All of them confirmed as MPS by the enzyme assay in leukocytes and fibroblast skin culture. We started ERT with ${\alpha}$-L-iduronidase(Aldurazyme$^{(R)}$) to MPS I and did recombinant human iduronate-2-sulfatase (Elaprase$^{(R)}$) to MPS II patients as recommended dose as over 5 years old. But for MPS II patient who was 4 month old, we started ERT by recombinant human IDS (Elaprase$^{(R)}$) with reduced dose 0.1 mg/kg and increased dose every 2 weeks by 0.1mg/kg up to 0.5mg/kg IV infusion. During ERT, all patients had no adverse effects and the excretion of GAGs were decreased. We have evaluated other clinical symptoms such as liver/ spleen volume, heart function and neurologic evaluation. We describe a successful ERT to MPS I and MPS II patient under 5 years old without any adverse event. It indicates that ERT in young children are well tolerated and that it has several effects which may confer clinical benefits with long-term therapy.

• 한국임상약학회지
• /
• 제7권2호
• /
• pp.64-66
• /
• 1997

Zinc is employed in body cell growth and immune function. Zinc deficiency causes growth retardation, night blindness, delay of wound healing, skin disorders, alopecia, et al. Pharmacokinetic study of zinc in Korean has not yet been proceeded to apply to patient. In this study, we investigated to adjust zinc dosage for maintaining constant zinc optimum serum level. Five NPO inpatients (3 males, 2 females) in Seoul National University of Hospital were evaluated, retrospectively. Zinc was mixed with parenteral nutrition solution and administrated intravenously in 24 hour-continuous infusion, and zinc dosage range was 0.17-0.45 mg/kg/day. AUC to zinc dose (AUC/Dose) was $2.421\pm1.007\;kg{\cdot}min/ml.$ 0.5 mg/kg/day zinc administration may achieve the plasma zinc concentration of $120\;{\mu}g/dl.$(Kor. J. Clin. Pharm. 1997; 7: 64-66)

• Journal of Medicine and Life Science
• /
• 제20권2호
• /
• pp.89-93
• /
• 2023

We present three cases of patients with breast cancer and psoriasis who received radiotherapy following breast-conserving surgery. One patient developed an extensive flare-up of psoriasis during chemotherapy. After discontinuing chemotherapy, she received conventional radiotherapy to the ipsilateral whole breast, axillary, and supraclavicular lymph nodes with 50.4 Gy in 28 fractions and boosted with 10 Gy in five fractions to the tumor bed. Two patients received hypofractionated whole-breast radiotherapy at a total dose of 40.05-42.4 Gy in 15-16 fractions. In all three cases, there was no flare-up of psoriatic events at least 6 months after the completion of radiotherapy. We hypothesized that there is a close relationship between psoriatic events and the extent of trauma rather than the daily dose of the fraction. Therefore, we confirmed that the effect of radiotherapy on psoriatic events is minimal if the radiation field size does not exceed that of the whole breast.

• Journal of Radiation Protection and Research
• /
• 제27권1호
• /
• pp.1-10
• /
• 2002

의료용 선형가속기에서 발생되는 고 에너지 광자선은 콜리메이터에 의하여 누출되며 치료두부(head), 콜리메이터, 환자를 포함한 치료실내의 모든 벽과 구성 물질들에 의하여 많은 산란선이 발생된다. 방사선치료는 종양에 따라서 최소한 40 Gy에서 80 Gy까지 조사되기 때문에 주위건강조직 특히 생식가능한 사람에 대한 생식선의 피폭선량을 평가하여야하며 종양치료에 영향을 주지 않은 범위에서 가능한 방법을 동원하여 피폭선량을 줄여야한다. 방사선 안전관리등의 기술기준에 관한 규칙(과학기술부령 제17호) 제3절 의료분야의 특별기준, 제44조(진료환자의 방사선 피폭)에 의하면 진료를 위한 환자 피폭선량을 합리적으로 달성 가능한 최소의 수준으로 유지하기 위한 절차를 구비하여야 하며 과학기술부 장관은 이에 준하는 의료시설 및 장비취급의 기술기준을 정하고 고시하여야한다고 명시 되어있다. 고 에너지방사선은 악성종양환자들의 치료성과를 향상시키는 동시에 치료후 방사선에 의한 만성효과가 발생 될 수 있기 때문에 주선속의 다양한 산란선과 누출선의 선질변화와 선량을 측정하고 생식선과 같은 주요장기를 산란선으로부터 차폐할 수 있는 기구를 제작 사용함으로서 방사선 피폭선량을 최대한으로 감소시킬 수 있었다. 고 에너지 방사선은 의료용 선형가속기(CLINAC 2100C/D. 2100C. 600C)에서 발생시킨 4, 6, 10 MV x-ray와 코발트원격치료장치(ALCYON II)의 코발트선원에서 방출되는 1.25 MV의 감마선을 이용하였다. 선량측정은 폴리스틸렌과 인체팬텀(Rando)사용하였으며 측정기는 이온함, TLD 및 필름을 사용하였다. 고 에너지 방사선에 의한 산란선은 장치의 콜리메이터 뿐만 아니라 치료실 벽 인체내부등 모든 방향에서 방사됨으로 납 벽돌에 의한 차폐율측정은 많은 변수를 가졌으며 고환인 경우에는 3면이 모두 차폐되도록 항아리모양으로 제작하였다. 태아인 경우 태아가 위치하고 있는 골반위에 육교모양의 선반을 만들고 그 위에 납 벽돌을 장치하도록 고안하였다. Co-60 감마선, 4 MV x-선, 10 MV x-선에서 발생되는 누출선량과 산란선량에 의한 평균 피폭선량은 조사면 중심으로부터 10, 30, 60cm 거리에서 조사면내 최대선량에 대하여 각각 $10^{-2},\;10^{-3},\;10^{-4}$의 비율로 측정되었으며 거리에 따라 지수함수로 줄어들었다. 흉부에 국한된 종양을 10 MV x-ray, $12{\times}12 cm^2$ 조사면으로 치료하였을 때 자궁에 받는 피폭선량은 0.9 mGy/Gy이며 고환이 받는 피폭선량은 0.6 mGy/Gy 이었으며 체장과 신장은 각각 4.8 mGy/Gy 와 2.5 mGy/Gy이다 10 MV x-선, $14{\times}14cm^2$ 조사면 경계로부터 10 cm 밖에서 납벽돌의 반가층 두께는 약 9.0 mm 이였고 20cm 밖에서는 반가층 두께가 약 6.5 mm로 측정되었다. 복부에 위치한 악성종양을 60 Gy 조사하였을 경우 태아가 위치하고 있는 자궁의 피폭선량은 약 370 mGy이고 이곳을 10 mGy이하가 되도록 차폐하려면 약 6.2 cm두께의 납 벽돌을 자궁위에 장착하여야 하며 골반치료시 고환에 10 mGy이하가 되도록 차폐하려면 약 5 cm 두께의 납 항아리가 요구된다. 고 에너지 고 준위 방사선치료시 고환은 3면을 항아리모양으로 차폐할 수 있어 피폭선량을 상당히 줄일 수 있으며 자궁인 경우 체내에서 산란된 선량의 차폐는 불가능하였다.

• Journal of Korean Neurosurgical Society
• /
• 제50권1호
• /
• pp.68-71
• /
• 2011

We present a case of Neuro-Behçet's disease with an unpredictable clinical course. A 47-year-old man was admitted to the neurosurgery department of our hospital with a mild headache. Three days after admission, his consciousness suddenly decreased and respiratory distress progressed rapidly. A brain MRI revealed that the previously observed abnormal signal had extended markedly to both the thalamic areas and the entire brain stem, and the surrounding brain parenchyma were compressed by cerebral edema. Based on the patient's symptoms of recurrent oral and genital ulcers, skin lesions, and uveitis, a rheumatologist made a diagnosis of Behçet's disease with CNS involvement. The patient was treated with high-dose methylprednisolone with respiratory assistance in the intensive care unit for 9 days and his neurologic symptoms improved remarkably. Neuro-Behçet's disease must be considered in the differential diagnosis in rapidly deteriorated young neurological patients along with a stroke, low-grade glioma, multiple sclerosis, and occlusive venous disease.

• The Korean Journal of Pain
• /
• 제8권1호
• /
• pp.124-126
• /
• 1995

Atopic allergy implies a familial tendency to manifest alone or in combination such as asthma, rhinitis, urticaria and atopic dermatitis. The patient with atopic dermatitis shows a variety of humoral and cell-mediated immune dysfunction, including an elevation of serum IgE level, multiple positive immediate skin tests to a variety of antigen. A 30 year old female patient suffering from an atopic dermatitis on face, has been administered a stellate ganglion block(SGB) with a 1% mepivacaine 5cc. She complained of bronchial hyperresponsivness such as cough, soreness, and inspiration difficulty for 5 days following the treatment, so we have reduced 1% mepivacaine dose from 5cc to 3cc. She had no complain of bronchial hyperresponsivenss and the lesion of atopic dermatitis was improved. From our result we conclude that SGB appears to be a good choice for the treatment of the atopic dermatitis and only 1% mepivacaine 3cc is possible in complete SGB.

• 한국의학물리학회지:의학물리
• /
• 제13권2호
• /
• pp.74-78
• /
• 2002

환자 치료시 환자의 위치고정과 매번 치료에서 환자 치료 자세의 재현을 위해 사용하는 고정물(immobilizer)중 Vacuum cushion을 사용시 Vacuum cushion으로 인해 예상되는 표면선량 또는, 투과량의 변화들을 측정하여 Vacuum cushion의 특성을 평가하였다. 광자선 에너지 4 MV (Varian 4/100, 미국), 6MV, 15 MV (Varian CL2100C/D, 미국)에 대해서 조사면의 크기를 5$\times$5, 10$\times$10, 20$\times$20, 30$\times$30, 40$\times$40 $\textrm{cm}^2$로, Vacuum cushion의 두께는 12, 32, 48 mm, 그리고 스티로폼이 없이 진공 봉지만 있는 경우로 변화해가며 Vacuum cushion에 대해 팬톰 표면에서 d$_{max}$까지의 선량을 측정하였다. 그 결과 vacuum cushion 두께에 대한 투과율은 0.9953-1.0043의 분포로 거의 차이가 없었다. 그리고 vacuum cushion의 두께가 두꺼워질수록, 환자가 받는 표면 선량은 증가하였다. 에너지, 조사면 크기에 대해 Vacuum cushion의 두께에 따라 표면 선량의 변화가 있었으나 6 MV와 15 MV에 대해 알려진 aquaplast의 데이타와 가장 두꺼운(48mm) vacuum cushion의 표면선량 증가율을 비교시 aquaplast보다 대략 16, 12% 낮아 임상에 적용하는데 무리가 있을 만큼 심각한 문제가 아니었다.